Upstream Bio, Inc. UPB Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Septerna, Inc.SEPN

——

Kymera TherapeuticsKYMR

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

See full

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total equity$304.0M-31.8%

Total assets$318.1M-30.3%

Cash flow

See full

Operating cash flow-$47.9M-16.2%

CapEx$54.0K-70.8%

Free cash flow-$30.7M-55.0%

Valuation

See full

Market cap$346.11M-40.9%

Enterprise value$250.5M-51.4%

P/S104.2×-151×

Profitability

See full

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

See full

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Upstream Bio, Inc.’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s proceeds from issuance of common stock relating to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Upstream Bio, Inc.'s proceeds from issuance of common stock relating to employee stock plans?: Upstream Bio, Inc. (UPB) reported proceeds from issuance of common stock relating to employee stock plans of $49K in Q4 2025.